Bristol Myers Squibb - Eight-Year Data for Opdivo Plus Yervoy Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%...

Related Keywords

United States ,Taiwan ,South Korea ,Japan ,China ,America ,American ,Nizar Tannir ,Dana Walker ,Bristol Myers Squibb ,Drug Administration ,Division Of Cancer Medicine ,Company Opdivo ,European Union ,University Of Texas ,International Metastatic ,Md Anderson Cancer Center ,Exchange Commission ,Department Of Genitourinary Medical Oncology ,American Society Of Clinical Oncology ,Database Consortium ,Ono Pharmaceutical Co ,Myers Squibb ,Clinical Oncology ,Cancers Symposium ,Hazard Ratio ,Confidence Interval ,Genitourinary Medical Oncology ,Cancer Medicine ,Better Future ,Ono Pharmaceutical ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,News Publishing ,Markets ,